Models of pure FTD, such as human iPSC derived-neurons expressing 10 + 16 MAPT mutations have a more significant reduction in ATP production compared to controls when treated with the glycolysis inhibitor iodoacetic acid, also suggesting impaired glucose metabolism (Esteras et al., 2017). Here, MAPT is linked to frontotemporal dementia.